Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study

AIMS: To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co‐transporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin on urinary glucose excretion (UGE), renal threshold for glucose excretion (RT(G)) and postprandial plasma glucose (PPG) excursion in he...

Descripción completa

Detalles Bibliográficos
Autores principales: Sha, S., Polidori, D., Farrell, K., Ghosh, A., Natarajan, J., Vaccaro, N., Pinheiro, J., Rothenberg, P., Plum‐Mörschel, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680204/
https://www.ncbi.nlm.nih.gov/pubmed/25421015
http://dx.doi.org/10.1111/dom.12418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680204/
https://www.ncbi.nlm.nih.gov/pubmed/25421015
http://dx.doi.org/10.1111/dom.12418

Ejemplares similares